Promoter holding
64.27%
FB
Fortune Biotech Ltd - Due diligence report
A 360° intelligence report on Fortune Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signal…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Fortune Biotech — 360° Intelligence Report
Generated from MCA filings & public records78/100
Trust Score
Low Risk
Fortune Biotech is assessed as Low Risk with a Trust Score of 78/100. Fortune Biotech is an active public limited indian non-government company incorporated in 1993, operating in the Agriculture sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Fortune Biotech Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
78/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
76/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (73.64 cr) · 25 satisfied (77.17 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| City Union Bank Limited | 1 | 48.0 cr |
| The South Indian Bank Limited | 1 | 48.0 cr |
| Others | 7 | 48.0 cr |
| State Bank Of India | 3 | 48.0 cr |
| Pridhvi Asset Reconstruction And Securitisation Company Limited | 2 | 48.0 cr |
| Icici Banking Corporation Ltd | 3 | 48.0 cr |
Compliance Score: 76/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 1 auditor resignation(s) filed - latest: Y.K.REDDY&ASSOCIATES on 2014-10-25.
- 2 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| VINDHYA ANNAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KANISHKA TUMU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ramasamy Sambasivam Annadurai | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Manoj Kumar Jain | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAGHAVACHARYA VASUDEVAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIKHYATH ANNAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a majority stake - exact percentages are part of the full report.
Key managerial personnel: KANISHKA TUMU (CFO) · VIKHYATH ANNAM (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 55
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Asset base grew 1.42 - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 32+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 2.1x in a year.
3 director exits within 2 years.
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 73.64 cr already registered.
- Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
14 Feb 2025
Charge created
City Union Bank Limited - 73.64 cr
11 Feb 2025
Director ceased
MANISH TARACHAND PANDE
24 Jan 2025
Charge satisfied
Others
Charge satisfied
The South Indian Bank Limited
29 Sep 2024
Director ceased
Ramasamy Sambasivam Annadurai
19 Sep 2024
Director appointed
Ramasamy Sambasivam Annadurai (Director)
Director appointed
Manoj Kumar Jain (Nominee Director)
Director ceased
KISHOR KUMAR RUNGTA
04 Aug 2023
Charge satisfied
Others
23 Feb 2023
Director ceased
RAGHAVACHARYA VASUDEVAN
30 Mar 2022
Charge created
Others - 74.50 Lakh
25 Dec 2021
Director appointed
RAGHAVACHARYA VASUDEVAN (Director)
02 Sep 2020
Charge created
Others - 1.49 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Saimirra | U24232TN2000PTC044315 | Chennai, Tamil Nadu, India |
| Mepromax Life Sciences Private Limited | U24231GJ2005PTC045918 | Wadhwan, Gujarat, India |
| Brooks Laboratories | L24232HP2002PLC000267 | Nalagarh, Himachal Pradesh, India |
| Vasudha Specialities Private Limited | U24110MH1986PTC039676 | Panvel, Maharashtra, India |
| Enicar Pharmaceuticals Private Limited | U24230MH1994PTC079450 | Boisar, Maharashtra, India |
| Sudarshan Chempro Private Limited | U24119KA1999PTC025841 | Bangalore, Karnataka, India |
| Spectrochem Pvt Ltd | U24110MH1982PTC028448 | Mumbai, Maharashtra, India |
| Devarsons Industries Private Limited | U99999GJ1961PTC001390 | Na, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Fortune Biotech before audits and certifications: compliance score 76/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Fortune Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Fortune Biotech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 78/100, distress signals and MSME payment-delay disclosures - know whether Fortune Biotech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Fortune Biotech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Fortune Biotech an active company?
Fortune Biotech has MCA status “Active” with a compliance score of 76/100 (Low Risk).
Is Fortune Biotech financially healthy?
Fortune Biotech has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Fortune Biotech?
Its overall Trust Score is 78/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Fortune Biotech?
Promoters hold a majority stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Fortune Biotech have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 25 earlier charge(s) stand satisfied.
Is Fortune Biotech up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 76/100 (Low Risk).
Is it risky to lend to Fortune Biotech?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
